# MMP-12 and post-stroke brain damage

> **NIH NIH R01** · UNIVERSITY OF ILLINOIS AT CHICAGO · 2021 · $347,587

## Abstract

Project Summary/Abstract
At present, tissue-type plasminogen activator (tPA) is the only FDA approved stroke therapy. tPA establishes
reperfusion by thrombolysis of clots, but only a small subset of patients is eligible for tPA therapy. Moreover,
the brain damage that occurs before and after tPA therapy is still an unmet clinical need. Identifying new
therapeutic targets helps in developing novel and potent drugs to curtail post-stroke secondary brain damage.
Our recent studies have shown that elevation of matrix metalloproteinase-12 (MMP-12) during reperfusion
following transient focal ischemia in rodents contributes to BBB damage, apoptosis, and brain infarction. We
currently hypothesize that the induction of MMP-12 contributes to post-stroke pathophysiology and
compromises the neurologic outcome. Aim 1 is to characterize the role of MMP-12 in post-stroke brain
damage and neurological recovery in both males and females as well as in a second species. Aim 2 is to
unravel the source of MMP-12 and elucidate the molecular mechanisms underlying MMP-12-induced brain
damage after stroke. Aim 3 is to investigate the efficacy of post-ischemic MMP-12 suppression in aged
animals and animals with hypertension. We will use state of the art techniques including the shRNA-mediated
knockdown of target genes by nanoparticle-mediated delivery of plasmids, suture model middle cerebral artery
occlusion procedure, FACS analysis, and transmission electron microscopy to execute the proposed
experiments. The long-term goal of this project is to develop post-stroke therapies that modulate MMP-12 to
prevent secondary brain damage and promote neurological recovery.

## Key facts

- **NIH application ID:** 10217264
- **Project number:** 5R01NS102573-04
- **Recipient organization:** UNIVERSITY OF ILLINOIS AT CHICAGO
- **Principal Investigator:** Krishna Kumar Veeravalli
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $347,587
- **Award type:** 5
- **Project period:** 2018-09-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10217264

## Citation

> US National Institutes of Health, RePORTER application 10217264, MMP-12 and post-stroke brain damage (5R01NS102573-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10217264. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*